千金药业发行股份购买资产事项将于8月18日上会

Core Viewpoint - The Shanghai Stock Exchange's Mergers and Acquisitions Review Committee is scheduled to hold its 12th review meeting for 2025 on August 18, focusing on the asset purchase proposals from Qianjin Pharmaceutical [1] Group 1: Company Actions - Qianjin Pharmaceutical plans to acquire a 28.92% stake in Qianjin Xiangjiang Pharmaceutical from Zhuzhou Guotou and Liebang Kangtai through a share issuance [1] - The company also intends to purchase a 68% stake in Qianjin Xieli Pharmaceutical from Zhuzhou Guotou and 21 individual natural persons, using a combination of share issuance and cash payment [1]